Plain-English translation of NCT05881265 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether chidamide and venetoclax—two medications used together—can help patients whose acute promyelocytic leukemia (APL) has stopped responding to the standard treatment of retinoic acid and arsenic. Researchers believe that this medication combination might work against cancer cells that have become resistant to traditional therapy by targeting a specific protein that drives the disease.
While standard treatment works well for most APL patients, some people's cancer stops responding to it, leaving them with limited options. This trial exists to find a new treatment path for these patients whose cancer has become resistant to current therapies.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the two medications together as part of treatment for your resistant leukemia. The trial will track how well the treatment works and how you respond to it over time. You would be cared for at one of several medical centers participating in this study, with regular monitoring to ensure safety and effectiveness.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China